David Meek

In July 2016, the board of directors of Ipsen (Euronext: IPN), a French pharmaceutical company, appointed Meek as chief executive officer.

In July 2016, the board of directors of Ipsen (Euronext: IPN; ADR: IPSEY) appointed Meek as chief executive officer, effective July 18, 2016. Meek will be based at Ipsen's headquarters in Boulogne-Billancourt, a suburb of Paris.

He was executive vice-president and president of the oncology division of Baxalta Inc., which was recently acquired by Shire (July 2015 – July 2016 based in Cambridge, Massachusetts).

He later joined Baxter International Inc. as head of oncology division (July 2014 – June 2015, based in Cambridge, Massachusetts).

He has not only been in the pharmaceutical industry, however, and before joining Baxter he was the COO of Endocyte ($ECYT) from August 2012 to July 2014, based in Indianapolis.

He later joined Novartis Pharmaceuticals ($NVS), where he ran the company's respiratory and dermatology franchise in Switzerland (January 2005 – June 2007) before heading up operations in Canada (CEO & president, June 2007 – January 2010) and later running its oncology business in Europe (January 2010 – August 2012).

In January 2001, he began his career as national field sales director CNS and primary care in Janssen Biotech, Pharmaceutical Companies of Johnson & Johnson (until December 2004 based in Titusville, New Jersey).

David Meek graduated from Finneytown High School in 1981, and went on to attend University of Cincinnati. There, he enrolled in the ROTC program, and after university, served in Operation Desert Storm as a Second Lieutenant. He earned a Bronze Star Medal for his service.

David Meek (born September 12, 1963) is an American businessman. He held various global executive positions in major pharmaceutical and biotechnology companies.